Medidata Solutions
announced Clinverse as the 13th partner to join its
Technology Partner Program
, for solution providers that have leveraged Medidata products for data sharing with their clinical systems. Clinverse has been recognized for a new integration between its ClinPay™ eClinical commerce network and the
Medidata Rave
system for clinical data capture, management, and reporting. Using Medidata Web Services open web application programming interfaces (APIs), automatic data sharing between the two systems enables sponsors and CROs to make more efficient, accurate and timely investigator payments, which can directly impact site satisfaction, retention, and productivity.
A global technology company specializing in solutions for the financial management of clinical trials, Clinverse provides sponsors and CROs with a comprehensive solution to address the historically lengthy and error-prone site payment process. ClinPay is a robust accounting solution with global payment capabilities that can manage site payments in 130 currencies. Replacing tools and approaches that are heavily manual and paper-based, ClinPay electronically tracks investigator grants and compares actual terms in agreements with trial milestone data to make accurate payments to investigators for completed patient procedures.
The integration means that customers who enter clinical data from trial subjects into Medidata Rave automatically trigger payment milestones in ClinPay. With the automatic import of trial milestone data from Rave into ClinPay, both investigator sites and sponsor staff no longer have to manually enter the same trial milestone data into ClinPay. As a result, ClinPay receives information earlier about the completion of a negotiated term from the investigator contract, such as a patient visit or a specific procedure, and rapidly issues appropriate electronic payments. Consequently, a process that previously required several manual steps and often duplicative data entry is now largely electronic and automatic, enabling sites to be paid more quickly and more accurately. Moreover, sites are freed up to focus on clinical trials rather than spending time invoicing and tracking their payments. Increasingly, investigator sites expect this level of process automation and system integration from sponsors and CROs.
ClinPay’s web-based interface also provides sites with transparency into the status of their contracts and payments. The integration with Medidata Rave means that ClinPay provides sites with even earlier access to payment status with audit ability.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.